Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

trastuzumab and hyaluronidase-oysk (Herceptin Hylecta)

trastuzumab and hyaluronidase-oysk is an FDA-licensed reference biologic from Genentech, Inc..

351(a) biologicBLA 761106 Genentech, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2019

Reference product

Originator biologic
351(a)BLA 761106

Herceptin Hylecta trastuzumab and hyaluronidase-oysk

Genentech, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for trastuzumab and hyaluronidase-oysk from the RCSB Protein Data Bank (PDB 1N8Z).

3D molecular structure of trastuzumab and hyaluronidase-oysk (PDB entry 1N8Z)

Interactive biological assembly from PDB entry 1N8Z. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference trastuzumab and hyaluronidase-oysk product.

    7 yr 8 mo ago

trastuzumab and hyaluronidase-oysk: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for trastuzumab and hyaluronidase-oysk.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.